Insights

Gathering insights about Jaguar…

Similar companies to Jaguar

Jaguar Tech Stack

Jaguar uses 8 technology products and services including Crazy Egg, Facebook Pixel, Cloudflare, and more. Explore Jaguar's tech stack below.

Crazy Egg
Analytics
Facebook Pixel
Analytics
Cloudflare
Content Management System
AngularJS
Javascript Frameworks
Swiper
Javascript Libraries
Web Vitals
Javascript Libraries
Node.js
Programming Languages
Apache HTTP Server
Web Servers

Media & News

Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi
Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi® and Canalevia®-CA1, which has the potential to provide Jaguar up to an additional $22M with milestones and other potential future payments Near-term milestones for intestinal failure program buttressed by groundbreaking results of parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients Associated with significant toxicities to patients, PS has a lethal natural history, and PS reduction can potentially extend and save lives Jaguar's rare-disease pipeline is the subject of ongoing BD discussions with potential partners, targeting NDA-ready data in 12-18 months Jaguar presenting January 22 at Sequire Investor Summit in Puerto Rico; click here to register for event Click here to view replay of Jaguar's January 15 fireside chat during Lytham Partners Healthcare Investor Summit SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 22, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today provided updates regarding the company's strategic focus on its rare disease development program for crofelemer, which is focused on near-term milestones for the treatment of intestinal failure in patients with short bowel syndrome (SBS-IF) and microvillus inclusion disease (MVID). The company has received Orphan Drug Designation for both diseases for crofelemer in the US and EU.
Jan 22, 2026 | www.accessnewswire.com
Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts
SAN FRANCISCO, CA / ACCESS Newswire / January 14, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, January 15, 2026 at the Lytham Partners Healthcare Investor Summit. Participation Instructions for Jaguar's Virtual Presentation at the Lytham Partners Healthcare Investor Summit When: Thursday, January 15, 2026 at 3:30 PM Eastern Registration link for conference: Click Here Replay: A replay of the webcast will be available through the same link (Click Here) About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain.
Jan 14, 2026 | www.accessnewswire.com
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
$18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing conditions) Up to additional $20M in milestone and other future payments Future Pak becomes exclusive U.S. marketer for Mytesi® and Canalevia®-CA1 Jaguar continues to be the manufacturer of Mytesi and Canalevia-CA1 Meaningful non-dilutive capital enables Jaguar to focus on its rare-disease pipeline, which is the subject of ongoing BD discussions with other potential partners SAN FRANCISCO, CA / ACCESS Newswire / January 12, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that its wholly-owned subsidiary Napo Pharmaceuticals, Inc. (collectively, with Jaguar Health, Inc., "Jaguar") has entered into a U.S. licensing agreement with an affiliate of privately held Future Pak, LLC ("Future Pak"). Under the terms of the agreement, Future Pak will be the exclusive marketer for Mytesi (crofelemer), Jaguar's FDA-approved novel prescription drug for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy, and Canalevia-CA1, Jaguar's crofelemer prescription drug for the treatment of chemotherapy-induced diarrhea in dogs.
Jan 12, 2026 | www.accessnewswire.com
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication
Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure Associated with significant toxicities to patients, PS has a lethal natural history, and PS reduction can potentially extend and save lives SAN FRANCISCO, CA / ACCESS Newswire / January 6, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that an article published December 29, 2025 in HEALTH, a bi-monthly English and Arabic healthcare magazine in the United Arab Emirates, discusses the groundbreaking results of the ongoing and independent proof-of-concept study of crofelemer in pediatric patients in the UAE with intestinal failure due to the orphan diseases short bowel syndrome (SBS-IF) and microvillus inclusion disease (MVID). As announced, the initial results of this study were presented November 8, 2025 at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting by the study's primary investigator, Dr. Mohamad Miqdady, Division Chief of the Pediatric Gastroenterology, Hepatology & Nutrition Division at Sheikh Khalifa Medical City, a tertiary care center in Abu Dhabi in the UAE.
Jan 06, 2026 | www.accessnewswire.com
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it received notice from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) on January 1, 2026 that the company has been awarded a $240,000 grant. Canalevia-CA1 is currently conditionally approved for chemotherapy-induced diarrhea (CID) in dogs.
Jan 02, 2026 | www.accessnewswire.com
Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Update
Jaguar Animal Health, Inc. (NASDAQ: JAGX - Get Free Report) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 245,697 shares, an increase of 227.7% from the November 30th total of 74,987 shares. Currently, 7.1% of the company's stock are sold short. Based on
Dec 26, 2025 | www.defenseworld.net
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in October 2025 with the FDA in support of a possible expedited approval pathway SAN FRANCISCO, CA / ACCESS Newswire / December 15, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals' (Napo's) independent investigator at a leading SBS-IF treatment institution submitted an abstract describing preliminary findings from a clinical trial evaluating a novel oral liquid formulation of crofelemer in adult SBS-IF patients. This abstract is for consideration for presentation at the May 2-5, 2026 Digestive Disease Week® conference.
Dec 15, 2025 | www.accessnewswire.com

Jaguar's Email Address Formats

Jaguar uses at least 1 format(s):

Jaguar Email Formats	Example	Percentage
F.Last@jaguar.com	J.Doe@jaguar.com	64%
FLast@jaguar.com	JDoe@jaguar.com	20%
First.Last@jaguar.com	John.Doe@jaguar.com	15%
FL@jaguar.com	JD@jaguar.com	1%

Frequently Asked Questions

Where is Jaguar's headquarters located?

Jaguar's main headquarters is located at Birmingham, England cv3 4lf United Kingdom. The company has employees across 5 continents, including EuropeNorth AmericaAsia.

What is Jaguar's phone number?

You can contact Jaguar's main corporate office by phone at

+1-305-444-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Jaguar's stock symbol?

Jaguar is a publicly traded company; the company's stock symbol is JAGX.

What is Jaguar's official website and social media links?

Jaguar's official website is jaguar.com and has social profiles on LinkedIn.

How much revenue does Jaguar generate?

As of February 2026, Jaguar's annual revenue is estimated to be $304K.

What is Jaguar's NAICS code?

Jaguar's NAICS code is 3361 - Motor Vehicle Manufacturing.

How many employees does Jaguar have currently?

As of February 2026, Jaguar has approximately 10K employees across 5 continents, including EuropeNorth AmericaAsia. Key team members include Chief Executive Officer: T. M.Director: E. A.Director: J. S.. Explore Jaguar's employee directory with LeadIQ.

What industry does Jaguar belong to?

Jaguar operates in the Motor Vehicle Manufacturing industry.

What technology does Jaguar use?

Jaguar's tech stack includes Crazy EggFacebook PixelCloudflareAngularJSSwiperWeb VitalsNode.jsApache HTTP Server.

What is Jaguar's email format?

Jaguar's email format typically follows the pattern of F.Last@jaguar.com. Find more Jaguar email formats with LeadIQ.

Jaguar

Q: What is Jaguar's official website and social media links?

Jaguar's official website is jaguar.com. Jaguar has social profiles on LinkedIn.

Q: How many employees does Jaguar have currently?

Jaguar has approximately 10K employees.

Q: What technology does Jaguar use?

Jaguar's tech stack includes PWA, jQuery, yepnope.js, Webpack, Google Tag Manager.

Motor Vehicle ManufacturingEngland, United Kingdom10001+ Employees

Copy nothing.

Company Overview

Headquarters: Birmingham, England cv3 4lf United Kingdom
Phone number: +1-305-444-****
Website: jaguar.com
Stock Symbol: JAGX
NAICS Code: 3361 - Motor Vehicle Manufacturing
Employees: 10001+

Media & News

Funding & Financials

$10M$25M
Jaguar's revenue is estimated to be in the range of $10M$25M

Funding & Financials

$10M$25M
Jaguar's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Jaguar

Maserati

Lexus

Ferrari

Tesla

Jaguar Tech Stack

Media & News

Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Update

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Jaguar's Email Address Formats

Frequently Asked Questions

Where is Jaguar's headquarters located?

What is Jaguar's phone number?

What is Jaguar's stock symbol?

What is Jaguar's official website and social media links?

How much revenue does Jaguar generate?

What is Jaguar's NAICS code?

How many employees does Jaguar have currently?

What industry does Jaguar belong to?

What technology does Jaguar use?

What is Jaguar's email format?

Jaguar

Company Overview

Media & News

Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?